http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8b4f229a5fdb8befeff504881dd095ad
Outgoing Links
| Predicate | Object |
|---|---|
| family-name | Kaelin |
| name | William G. Kaelin William G Kaelin |
| given-name | William G. William G |
| organization-name | Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts The Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02115. Howard Hughes Medical Institute Department of Adult Oncology, Dana‐Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School Boston MA 02115 USA; Howard Hughes Medical Institute Chevy Chase MD 20815 USA Author's Affiliation: Howard Hughes Medical Institute, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts Authors' Affiliations: Departments of 1Medical Oncology and 2Cancer Biology, Dana-Farber Cancer Institute; Departments of 3Medicine and 4Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston; 5Broad Institute, Cambridge, Massachusetts; 6Howard Hughes Medical Institute, Chevy Chase, Maryland; Authors' Affiliations: Departments of 1Medical Oncology and 2Cancer Biology, Dana-Farber Cancer Institute; Departments of 3Medicine and 4Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston; 5Broad Institute, Cambridge, Massachusetts; 6Howard Hughes Medical Institute, Chevy Chase, Maryland; Authors' Affiliations: Departments of 1Medical Oncology and 2Cancer Biology, Dana-Farber Cancer Institute; Departments of 3Medicine and 4Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston; 5Broad Institute, Cambridge, Massachusetts; 6Howard Hughes Medical Institute, Chevy Chase, Maryland; Authors' Affiliations: Departments of 1Medical Oncology and 2Cancer Biology, Dana-Farber Cancer Institute; Departments of 3Medicine and 4Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston; 5Broad Institute, Cambridge, Massachusetts; 6Howard Hughes Medical Institute, Chevy Chase, Maryland Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115. Department of Adult Oncology; Howard Hughes Medical Institute, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115 Department of Adult Oncology and Howard Hughes Medical Institute, Dana–Farber Cancer Institute and Harvard Medical School, Boston, MA 02115 Dana-Farber Cancer Institute and Howard Hughes Medical Institute, Harvard Medical School, Boston, MA 02115, USA. 7Dana-Farbr Cancer Institute, Howard Hughes Medical Institute, Boston, Massachusetts; Howard Hughes Medical Institute, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Boston, MA 02115, USA. Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215;; Howard Hughes Medical Institute, Chevy Chase, MD 20815 The author is at the Howard Hughes Medical Institute, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA. Division of Chemistry and Chemical Engineering, Beckman Institute, California Institute of Technology, Pasadena, CA 91125; and Department of Adult Oncology, Dana–Farber Cancer Institute, Harvard Medical School, Boston, MA 02115 11Howard Hughes Medical Institute, Dana-Farber Cancer Institute, Boston, Massachusetts; 1Dana-Farber Cancer Institute and Harvard Medical School; 3Howard Hughes Medical Institute, Boston, Massachusetts 02115 Department of Molecular Oncology, Dana-Farber Cancer Institute, Harvard Medical School, and Howard Hughes Medical Institute, Boston, Massachusetts 02115 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA. Department of Medicine, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA.; Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA. Novartis Institute for Biomedical Research, Novartis Pharmaceuticals Corporation, 556 Morris Avenue, Summit, NJ 07901; and Howard Hughes Medical Institute, Dana-Farber Cancer Institute and Harvard Medical School, 44 Binney Street, Boston, MA 02115 1Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.; 3Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.; 6Howard Hughes Medical Institute, Chevy Chase, Maryland.; 10Broad Institute of Harvard and MIT, Cambridge, Massachusetts. Dana-Farber Cancer Institute, Boston, Massachusetts 02115 William G. Kaelin Jr, Harvard Medical School, Boston, MA 1Dana-Farber Cancer Institute; 2Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts 02115 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215;; Howard Hughes Medical Institute, Chevy Chase, MD 20815 Howard Hughes Medical Institute and Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts Dana-Farber Cancer Institute, Boston, MA 02115, USA. Department of Medical Oncology, Dana–Farber Cancer Institute and Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115; and Dana-Farber Cancer Institute and Harvard Medical School; Howard Hughes Medical Institute, Boston, Massachusetts 02115 Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115; Howard Hughes Medical Institute, Chevy Chase, Maryland 20815 Department of Medical Oncology, Dana-Farber Cancer Institute , Boston, Massachusetts , USA; Howard Hughes Medical Institute , Chevy Chase, Maryland , USA Department of Medical Oncology, Dana–Farber Cancer Institute, Harvard Medical School, Boston, MA 02215; HHMI, Chevy Chase, MD 20815 Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215 Department of Medical Oncology, Dana-Farber Cancer Institute, 02215, Boston, Massachusetts, USA;Howard Hughes Medical Institute, Chevy Chase, Maryland 20815, USA. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Howard Hughes Medical Institute (HHMI), Chevy Chase, MD 20815, USA. Dana–Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115; FibroGen, Inc., South San Francisco, CA 94080; Stowers Research Institute, Kansas City, MO 64110; and Howard Hughes Medical Institute, Chevy Chase, MD 20815 Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215;; Howard Hughes Medical Institute, Chevy Chase, MD 20815 Howard Hughes Medical Institute, Dana-Farber Cancer Institute, Boston, Massachusetts 02115 BOSTON, MASSACHUSETTS. Howard Hughes Medical Institute, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Boston, Massachusetts Howard Hughes Medical Institute, Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts 02115; Department of Medical Oncology Dana‐Farber Cancer Institute Harvard Medical School Boston MA USA; Howard Hughes Medical Institute Chevy Chase MD USA From the Department of Medical Oncology (J.M., Y.A.M., W.G.K.) and Department of Biostatistics and Computational Biology (D.N.), Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Harvard Medical School, Boston, Mass; Division of Cardiovascular Medicine (J.M., J.S., R.L.), Division of Nephrology, Department of Medicine (D.M.C.) and Pathology (R.F.P., S.S.), Brigham and Women’s Hospital, Harvard Medical School, Boston, Mass; and Howard Hughes Medical Institute, Chevy Chase, Md (W.G.K.). Department of Medical Oncology, Dana–Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115;; Howard Hughes Medical Institute, Chevy Chase, MD 20815; 9Dana-Farber/Harvard Cancer Center, Boston, Massachusetts. Department of Adult Oncology, Office M457, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA. Dana-Farber Cancer Institute and; Howard Hughes Medical Institute, Harvard Medical School, Boston, MA 02115, USA. From the Departments of Pediatric Oncology (J.K., K.V.H., J.A.P., C.M.C., A.I., C.B.W., K.A.J., S.G.D.) and Medical Oncology (W.G.K.), Dana–Farber Cancer Institute, Harvard Medical School, the Divisions of Hematology and Oncology (J.K., J.A.P., M.M.H., K.A.J., S.G.D.) and Endocrinology (A.J.W.) and the Departments of Surgery (B.R.W.), Pathology (S.O.V.), and Radiology (S.D.V.), Boston Children’s Hospital, Harvard Medical School, and the Manton Center for Orphan Disease Research and the Division of... Department of Medical Oncology, Dana–Farber Cancer Institute and Brigham and Womens Hospital, Harvard Medical School, Boston, MA 02215;; Howard Hughes Medical Institute, Chevy Chase, MD 02185 Howard Hughes Medical Institute and; Brigham and Womens Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115; and Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115 Department of Medical Oncology, Dana–Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115; FibroGen, Inc., South San Francisco, CA 94080; and Howard Hughes Medical Institute, Chevy Chase, MD 20815 Department of Medical Oncology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;; Howard Hughes Medical Institute, Chevy Chase, MD From the Howard Hughes Medical Institute, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA. 6Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.; 8Howard Hughes Medical Institute, Chevy Chase, Maryland. 1Dana-Farber Cancer Institute, Boston, Massachusetts; *Department of Medical Oncology, The Dana–Farber Cancer Institute and Harvard Medical School, Boston, MA 02115;; The Howard Hughes Medical Institute, Chevy Chase, MD 20815 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA. william_kaelin@dfci.harvard.edu Harvard Medical School , Boston, MA , USA; Department of Medical Oncology, Dana-Farber Cancer Institute , Boston, Massachusetts , USA Dana-Farber Cancer Institute; Harvard Medical School; Howard Hughes Medical Institute, Boston, Massachusetts 02115 Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115; Howard Hughes Medical Institute, Chevy Chase, Maryland 20815; Howard Hughes Medical Institute, Harvard Medical School, Boston, Massachusetts, USA. Howard Hughes Medical Institute, Chevy Chase, Maryland2Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115;; Howard Hughes Medical Institute, Chevy Chase, MD 20815 Howard Hughes Medical Institute, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA 02115, USA. 1Medical Oncology and Departments of; 4Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts;; 10Howard Hughes Medical Institute, Chevy Chase, Maryland Howard Hughes Medical Institute, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston, MA |
Incoming Links
Total number of triples: 278.